New drugs: How to decide which ones to prescribe

Family Practice Management

Volumn 13, Issue 6, 2006, Pages 33-35

  Mohler, Philip J ^a,b  

^a Division of Primary Care Partners   (United States)

^b Rocky Mountain Health Plans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DECISION MAKING; DRUG APPROVAL; DRUG THERAPY; ECONOMICS; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; SHORT SURVEY;

CLINICAL TRIALS; DECISION MAKING; DRUG APPROVAL; DRUG THERAPY; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; HUMANS; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 33745025561     PISSN: 10695648     EISSN: 15311929     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (8)

1. New drugs approved by the FDA in 2005. The Prescriber's Letter. February 2006:13.
2. Kroenke KE, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947-2955.
3. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143(6):415-426.
4. Evidence Report/Technology Assessment: Number 124: Update on Acute Bacterial Rhinosinusitis. Available at: http://www.ahrq.gov/downloads/pub/ evidence/pdf/rhinoupdate/rhinoup.pdf. Accessed May 8, 2006.
5. Ernst ME, Kelly MW, Hoehns JD, et al. Prescription medication costs: a study of physician familiarity. Arch Fam Med. 2000;9:1002-1007.
6. Inside clinical trials: testing medical products in people. FDA Consumer. January 2006. Available at: http://www.fda.gov/fdac/special/testtubetopatient/ trials.html. Accessed May 8, 2006.
7. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
8. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144:415-420.